IMMUNOGENIC PEPTIDES OF THE CYCLIN B1 TUMOR ANTIGEN
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 8, 2016
app pub date -
Jul 4, 2014
filing date -
Jul 5, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully